WO2006113678A3 - Methylation markers for diagnosis and treatment of cancers - Google Patents
Methylation markers for diagnosis and treatment of cancers Download PDFInfo
- Publication number
- WO2006113678A3 WO2006113678A3 PCT/US2006/014500 US2006014500W WO2006113678A3 WO 2006113678 A3 WO2006113678 A3 WO 2006113678A3 US 2006014500 W US2006014500 W US 2006014500W WO 2006113678 A3 WO2006113678 A3 WO 2006113678A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- silenced
- restoration
- markers
- accomplished
- treatments
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Two hundred ten markers are provided which are epigenetically silenced in one or more cancer types. The markers can be used diagnostically, prognostically, therapeutically, and for selecting treatments that are well tailored for an individual patient. Restoration of expression of silenced genes can be useful therapeutically, for example, if the silenced gene is a tumor-suppressor gene. Restoration can be accomplished by supplying non-methylated copies of the silenced genes or polynucleotides encoding their encoded products. Alternatively, restoration can be accomplished using chemical demethylating agents or methylation inhibitors. Kits for testing for epigenetic silencing can be used in the context of diagnostics, prognostics, or for selecting 'personalized medicine' treatments.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002604689A CA2604689A1 (en) | 2005-04-15 | 2006-04-17 | Methylation markers for diagnosis and treatment of cancers |
EP06758387A EP1869224A4 (en) | 2005-04-15 | 2006-04-17 | Methylation markers for diagnosis and treatment of cancers |
US11/887,616 US20090203639A1 (en) | 2005-04-15 | 2006-04-17 | Methylation Markers for Diagnoses and Treatment of Cancers |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67150105P | 2005-04-15 | 2005-04-15 | |
US60/671,501 | 2005-04-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006113678A2 WO2006113678A2 (en) | 2006-10-26 |
WO2006113678A3 true WO2006113678A3 (en) | 2009-06-18 |
Family
ID=37115840
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/014493 WO2006113671A2 (en) | 2005-04-15 | 2006-04-17 | Methylation markers for diagnosis and treatment of cancers |
PCT/US2006/014500 WO2006113678A2 (en) | 2005-04-15 | 2006-04-17 | Methylation markers for diagnosis and treatment of cancers |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/014493 WO2006113671A2 (en) | 2005-04-15 | 2006-04-17 | Methylation markers for diagnosis and treatment of cancers |
Country Status (4)
Country | Link |
---|---|
US (3) | US20100035970A1 (en) |
EP (2) | EP1869222A4 (en) |
CA (2) | CA2604852A1 (en) |
WO (2) | WO2006113671A2 (en) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090269736A1 (en) * | 2002-10-01 | 2009-10-29 | Epigenomics Ag | Prognostic markers for prediction of treatment response and/or survival of breast cell proliferative disorder patients |
DE602004031405D1 (en) * | 2003-12-11 | 2011-03-31 | Epigenomics Ag | Marker to predict the response to therapy or the survival rate of breast cancer patients |
SI1642905T1 (en) | 2004-10-02 | 2009-04-30 | Immatics Biotechnologies Gmbh | Immunogenic T-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes |
EP1907855A4 (en) * | 2005-07-12 | 2009-11-11 | Univ Temple | Genetic and epigenetic alterations in the diagnosis and treatment of cancer |
WO2007030930A1 (en) | 2005-09-13 | 2007-03-22 | National Research Council Of Canada | Methods and compositions for modulating tumor cell activity |
US7754428B2 (en) * | 2006-05-03 | 2010-07-13 | The Chinese University Of Hong Kong | Fetal methylation markers |
ES2539042T3 (en) * | 2006-06-02 | 2015-06-25 | Glaxosmithkline Biologicals S.A. | Identification procedure of whether a patient will respond to immunotherapy or not |
US7888127B2 (en) | 2008-01-15 | 2011-02-15 | Sequenom, Inc. | Methods for reducing adduct formation for mass spectrometry analysis |
CA2715774A1 (en) * | 2008-02-19 | 2009-08-27 | Oncomethylome Sciences Sa | Detection and prognosis of lung cancer |
US20110189653A1 (en) | 2008-03-21 | 2011-08-04 | Wim Van Criekinge | Detection and prognosis of cervical cancer |
US8372587B2 (en) * | 2008-04-14 | 2013-02-12 | Nihon University | Proliferative disease detection method |
BRPI0913578A2 (en) | 2008-05-14 | 2017-06-06 | Dermtech Int | diagnosis of melanoma and solar lentigo by nucleic acid analysis |
EP2297336A1 (en) * | 2008-05-29 | 2011-03-23 | Vib Vzw | Minichromosome maintenance complex interacting protein involved in cancer |
US9023819B2 (en) | 2008-06-09 | 2015-05-05 | National Chung Cheng University | Treatment of a disease or a condition associated with aberrant gene hypomethylation by a method involving tailored epigenomic modification |
US8053189B2 (en) * | 2008-11-03 | 2011-11-08 | Fina Biotech, S.L.U. | Method for the diagnosis of colorectal cancer |
EP2233590A1 (en) * | 2009-01-28 | 2010-09-29 | AIT Austrian Institute of Technology GmbH | Methylation assay |
US20120164238A1 (en) | 2009-02-03 | 2012-06-28 | Mdxhealth Sa | Methods of detecting colorectal cancer |
US8715928B2 (en) * | 2009-02-13 | 2014-05-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Molecular-based method of cancer diagnosis and prognosis |
EP2428584A4 (en) * | 2009-04-03 | 2012-10-10 | A & T Corp | Method for detection of colorectal tumor |
WO2011004837A1 (en) | 2009-07-08 | 2011-01-13 | 株式会社ACTGen | Antibody having anti-cancer activity |
WO2011036173A1 (en) * | 2009-09-24 | 2011-03-31 | Oncomethylome Sciences S.A. | Detection and prognosis of cervical cancer |
CA2928846A1 (en) | 2009-11-24 | 2011-06-03 | Alethia Biotherapeutics Inc. | Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume |
EP2598659B1 (en) | 2010-07-27 | 2015-03-11 | Genomic Health, Inc. | Method for using gene expression to determine prognosis of prostate cancer |
US20120202202A1 (en) * | 2011-01-28 | 2012-08-09 | Michael Xia Wang | Methods for detecting rare circulating cancer cells using dna methylation biomarkers |
US20140031257A1 (en) * | 2011-03-10 | 2014-01-30 | Oslo Universitetssykehus Hf | Methods and biomarkers for detection of gastrointestinal cancers |
ES2675727T3 (en) | 2012-02-13 | 2018-07-12 | Beijing Institute For Cancer Research | Method for in vitro estimation of tumorigenesis, metastasis or life expectancy and artificial nucleotide used |
CN104159611A (en) | 2012-02-22 | 2014-11-19 | 阿莱斯亚生物疗法股份有限公司 | Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer |
US20130189684A1 (en) * | 2013-03-12 | 2013-07-25 | Sequenom, Inc. | Quantification of cell-specific nucleic acid markers |
US9305756B2 (en) | 2013-03-13 | 2016-04-05 | Agena Bioscience, Inc. | Preparation enhancements and methods of use for MALDI mass spectrometry |
EP2806274A1 (en) * | 2013-05-24 | 2014-11-26 | AIT Austrian Institute of Technology GmbH | Lung cancer diagnostic method and means |
WO2016116922A1 (en) * | 2015-01-19 | 2016-07-28 | Rappaport Family Institute For Research In The Medical Sciences | Ubiquitin ligase kpc1 promotes processing of p105 nf-kappab1 to p50, eliciting strong tumor suppression |
WO2018127786A1 (en) * | 2017-01-06 | 2018-07-12 | Oslo Universitetssykehus Hf | Compositions and methods for determining a treatment course of action |
AU2018251770B2 (en) * | 2017-04-10 | 2024-03-14 | Dermtech, Inc. | Non-invasive skin-based detection methods |
US11242568B2 (en) * | 2017-12-29 | 2022-02-08 | City Of Hope | DNA methylation diagnostic test for breast cancer |
CA3090785A1 (en) | 2018-02-14 | 2019-08-22 | John Daniel Dobak Iii | Novel gene classifiers and uses thereof in non-melanoma skin cancers |
US11578373B2 (en) | 2019-03-26 | 2023-02-14 | Dermtech, Inc. | Gene classifiers and uses thereof in skin cancers |
CN110885375B (en) * | 2019-12-20 | 2021-07-02 | 南京融捷康生物科技有限公司 | Single-domain antibody specifically aiming at MMP-9 protein zinc ion binding domain, product and application |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004083399A2 (en) * | 2003-03-17 | 2004-09-30 | The Johns Hopkins University | Aberrantly methylated genes in pancreatic cancer |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5783672A (en) * | 1994-05-26 | 1998-07-21 | Immunex Corporation | Receptor for oncostatin M |
WO2002057414A2 (en) * | 2000-10-20 | 2002-07-25 | Expression Diagnostics, Inc. | Leukocyte expression profiling |
AU2002351828A1 (en) * | 2001-11-05 | 2003-05-19 | Deutsches Krebsforschungszentrum | Novel genetic markers for leukemias |
WO2003042661A2 (en) * | 2001-11-13 | 2003-05-22 | Protein Design Labs, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
EP2230299B1 (en) * | 2002-01-18 | 2011-12-07 | ZymoGenetics, Inc. | Novel cytokine ZCYTOR17 ligand |
IL163732A0 (en) * | 2002-03-07 | 2005-12-18 | Univ Johns Hopkins | Genomic screen for epigenetically silenced tumor suppressor genes |
US20040053304A1 (en) * | 2002-06-05 | 2004-03-18 | Case Western Reserve University | Methods and compositions for detecting cancers |
WO2004087957A2 (en) * | 2003-04-03 | 2004-10-14 | Oncomethylome Sciences S.A. | Hypermethylated genes and cervical cancer |
EP2003196A3 (en) * | 2003-06-09 | 2009-01-07 | The Regents of the University of Michigan | Compositions and methods for treating and diagnosing cancer |
-
2006
- 2006-04-17 US US11/887,418 patent/US20100035970A1/en not_active Abandoned
- 2006-04-17 WO PCT/US2006/014493 patent/WO2006113671A2/en active Application Filing
- 2006-04-17 CA CA002604852A patent/CA2604852A1/en not_active Abandoned
- 2006-04-17 CA CA002604689A patent/CA2604689A1/en not_active Abandoned
- 2006-04-17 WO PCT/US2006/014500 patent/WO2006113678A2/en active Application Filing
- 2006-04-17 EP EP06750515A patent/EP1869222A4/en not_active Withdrawn
- 2006-04-17 EP EP06758387A patent/EP1869224A4/en not_active Withdrawn
- 2006-04-17 US US11/887,616 patent/US20090203639A1/en not_active Abandoned
- 2006-10-13 US US11/580,245 patent/US20090215709A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004083399A2 (en) * | 2003-03-17 | 2004-09-30 | The Johns Hopkins University | Aberrantly methylated genes in pancreatic cancer |
Non-Patent Citations (4)
Title |
---|
KITKUMTHORN ET AL.: "Cyclin A1 promoter hypermethylation in human papillomavirus- associated cervical cancer.", BMC CANCER., vol. 6, no. 55, 8 March 2006 (2006-03-08), pages 1 - 9, XP008123611 * |
MULLER ET AL.: "Methylation of the cyclin A1 promoter correlates with gene silencing in somatic cell lines, while tissue-specific expression of cyclin A1 is methylation independent.", MOLECULAR AND CELLULAR BIOLOGY., vol. 20, no. 9, May 2000 (2000-05-01), pages 3316 - 3329, XP002978075 * |
See also references of EP1869224A4 * |
TOKUMARU ET AL.: "Inverse correlation between cyclin A1 hypermethylation and p53 mutation in head and neck cancer identified by reversal of epigenetic silencing.", CANCER RESEARCH., vol. 64, 1 September 2004 (2004-09-01), pages 5982 - 5987, XP008123553 * |
Also Published As
Publication number | Publication date |
---|---|
EP1869224A4 (en) | 2009-11-18 |
EP1869222A4 (en) | 2010-01-20 |
US20090203639A1 (en) | 2009-08-13 |
WO2006113671A3 (en) | 2009-04-23 |
WO2006113678A2 (en) | 2006-10-26 |
CA2604689A1 (en) | 2006-10-26 |
CA2604852A1 (en) | 2006-10-26 |
US20100035970A1 (en) | 2010-02-11 |
WO2006113671A2 (en) | 2006-10-26 |
WO2006113671A8 (en) | 2007-06-07 |
EP1869224A2 (en) | 2007-12-26 |
EP1869222A2 (en) | 2007-12-26 |
US20090215709A1 (en) | 2009-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006113678A3 (en) | Methylation markers for diagnosis and treatment of cancers | |
WO2009037438A8 (en) | Improved detection of mage-a expression | |
WO2006133022A3 (en) | Compositions and methods for decreasing microrna expression for the treatment of neoplasia | |
WO2006089233A3 (en) | Methods and systems for diagnosis, prognosis and selection of treatment of leukemia | |
WO2008021183A3 (en) | For the identification, assessment, and treatment of patients with cancer therapy | |
WO2008146309A3 (en) | Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment | |
WO2008117314A3 (en) | Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment | |
WO2005117553A3 (en) | Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients | |
EP2639318A3 (en) | Genetic polymorphisms associated with Psoriasis, methods of detection and uses thereof | |
WO2005116259A3 (en) | Use of gene expression profiling to predict survival in cancer patient | |
WO2007112330A8 (en) | Compositions and methods for detection, prognosis and treatment of colon cancer | |
WO2001068912A3 (en) | Diagnosis of diseases associated with tumor suppressor genes and oncogenes | |
EP2481806A3 (en) | Methods for differentiating pancreatic cancer from normal pancreatic function and/or chronic pancreatitis | |
WO2009012140A3 (en) | Drug selection for lung cancer therapy using antibody-based arrays | |
WO2008027912A3 (en) | Prediction of an agent's or agents' activity across different cells and tissue types | |
WO2005111211A8 (en) | Micronas and uses thereof | |
HUP0400668A2 (en) | Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof | |
WO2006009805A3 (en) | Combination of a chemotherapeutic agent and an antagonist of a gene product for treating tumors | |
WO2010105815A3 (en) | Improved detection of gene expression | |
WO2007022511A3 (en) | Listeria-induced immunorecruitment and activation, and methods of use thereof | |
AU2003302732A1 (en) | Method for identifying risk of breast cancer and treatments thereof | |
Arivett et al. | Draft genome of the multidrug-resistant Acinetobacter baumannii strain A155 clinical isolate | |
WO2007109733A3 (en) | Diagnostic and prognostic markers and treatment strategies for multiple sclerosis | |
WO2014193964A3 (en) | Prognostic and predictive breast cancer signature | |
WO2005007097A3 (en) | Breast cancer genes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2604689 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006758387 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11887616 Country of ref document: US |